CYTOKINETICS, INCORPORATED Proceeds from Debt, Net of Issuance Costs
CYTOKINETICS, INCORPORATED (CYTK) reported Proceeds from Debt, Net of Issuance Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2022-02-25
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for the quarter ending 2020-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for the quarter ending 2020-09-30 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for the quarter ending 2019-12-31 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for fiscal 2021 was $0.00.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for fiscal 2019 was $1.71M, a 82.72% decline from fiscal 2018.
- CYTOKINETICS, INCORPORATED proceeds from debt, net of issuance costs for fiscal 2018 was $9.90M, a 684.93% increase from fiscal 2017.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-25 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 derived: sum of 2 quarters · filed 2022-02-25 | $1.71M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.71M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $1.71M 10-Q · filed 2020-08-07 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $7.44M derived: sum of 2 quarters · filed 2021-02-26 | $9.90M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $7.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $9.90M 10-Q · filed 2019-11-01 | ||
| 2018-06-30 | $2.45M 10-Q · filed 2019-08-09 | |||
| 2017-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $1.26M derived: sum of 2 quarters · filed 2019-03-07 | $1.26M derived: sum of 3 quarters · filed 2019-03-07 | $1.26M 10-K · filed 2019-03-07 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 | $0.00 derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $0.00 10-Q · filed 2017-08-04 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 derived: sum of 4 quarters · filed 2018-03-05 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $0.00 derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $0.00 derived: sum of 2 quarters · filed 2018-03-05 | $0.00 derived: sum of 3 quarters · filed 2018-03-05 | $15.00M 10-K · filed 2018-03-05 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $0.00 derived: sum of 2 quarters · filed 2017-11-03 | $15.00M 10-Q · filed 2017-11-03 | $29.89M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $15.00M 10-Q · filed 2017-08-04 | $29.89M derived: sum of 3 quarters · filed 2018-03-05 | $29.89M derived: sum of 4 quarters · filed 2018-03-05 |
| 2016-03-31 | $15.00M 10-Q · filed 2017-05-04 | $29.89M derived: sum of 2 quarters · filed 2018-03-05 | $29.89M derived: sum of 3 quarters · filed 2018-03-05 | $29.89M derived: sum of 4 quarters · filed 2018-03-05 |
| 2015-12-31 | $14.89M derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-05 | $14.89M derived: sum of 2 quarters · filed 2018-03-05 | $14.89M derived: sum of 3 quarters · filed 2018-03-05 | $14.89M 10-K · filed 2018-03-05 |
| 2015-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q 6 month · filed 2016-12-15 | $0.00 derived: sum of 2 quarters · filed 2016-12-15 | $0.00 10-Q/A · filed 2016-12-15 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $0.00 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |